文献速递产科母胎医学

循环血管生成因子失衡在子痫前期及相关疾病病理生理中的作用

Imbalances in circulating angiogenic factors in the pathophysiology of preeclampsia and related disorders.
PubMed 文献 · Am J Obstet Gynecol · 2020-10-20

子痫前期是严重妊娠并发症,胎盘来源的循环血管生成因子失衡被认为是导致母体症状的原因。可溶性fms样酪氨酸激酶1升高而胎盘生长因子降低,这些变化先于临床症状出现并与疾病严重程度相关。自动化检测这些生物标志物有助于临床诊断和预测子痫前期,并具有很高的阴性预测值。

要点

  • 循环血管生成因子失衡先于子痫前期临床症状出现并与严重程度相关。
  • 可溶性fms样酪氨酸激酶1升高、胎盘生长因子降低是子痫前期的关键改变。
  • 血管生成生物标志物具有高阴性预测值,可用于排除疑似子痫前期。

核心结论

  • 胎盘来源的循环血管生成因子失衡是子痫前期母体症状的重要原因,相关生物标志物可用于临床诊断、预测和排除子痫前期。

研究设计与样本

  • 综述性文章,总结流行病学和实验研究证据,讨论循环血管生成因子在子痫前期及相关胎盘异常疾病中的作用。

主要发现

  • 子痫前期患者循环可溶性fms样酪氨酸激酶1水平显著升高,其配体胎盘生长因子的游离水平显著降低。
  • 这些血管生成因子的改变先于子痫前期临床症状出现,并与疾病严重程度相关。
  • 循环血管生成生物标志物在疑似子痫前期女性中具有很高的阴性预测值,可帮助排除临床疾病。

临床怎么用

  • 临床可检测血浆、血清和尿液中血管生成生物标志物,辅助子痫前期的诊断和预测。
  • 对疑似子痫前期女性,血管生成生物标志物高阴性预测值有助于排除疾病并减少不良结局。

局限性

  • 本文为综述,未报告原始研究的具体样本量、阈值或效应量;血管生成因子失衡的具体病因仍有争议。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Preeclampsia is a devastating medical complication of pregnancy that can lead to significant maternal and fetal morbidity and mortality. It is currently believed that there is abnormal placentation in as early as the first trimester in women destined to develop preeclampsia. Although the etiology of the abnormal placentation is being debated, numerous epidemiologic and experimental studies suggest that imbalances in circulating angiogenic factors released from the placenta are responsible for the maternal signs and symptoms of preeclampsia. In particular, circulating levels of soluble fms-like tyrosine kinase 1, an antiangiogenic factor, are markedly increased in women with preeclampsia, whereas free levels of its ligand, placental, growth factor are markedly diminished. Alterations in these angiogenic factors precede the onset of clinical signs of preeclampsia and correlate with disease severity. Recently, the availability of automated assays for the measurement of angiogenic biomarkers in the plasma, serum, and urine has helped investigators worldwide to demonstrate a key role for these factors in the clinical diagnosis and prediction of preeclampsia. Numerous studies have reported that circulating angiogenic biomarkers have a very high negative predictive value to rule out clinical disease among women with suspected preeclampsia. These blood-based biomarkers have provided a valuable tool to clinicians to accelerate the time to clinical diagnosis and minimize maternal adverse outcomes in women with preeclampsia. Angiogenic biomarkers have also been useful to elucidate the pathogenesis of related disorders of abnormal placentation such as intrauterine growth restriction, intrauterine fetal death, twin-to-twin transfusion syndrome, and fetal hydrops. In summary, the discovery and characterization of angiogenic proteins of placental origin have provided clinicians a noninvasive blood-based tool to monitor placental function and health and for early detection of disorders of placentation. Uncovering the mechanisms of altered angiogenic factors in preeclampsia and related disorders of placentation may provide insights into novel preventive and therapeutic options.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Rana S, Burke SD, Karumanchi SA, et al. Imbalances in circulating angiogenic factors in the pathophysiology of preeclampsia and related disorders. Am J Obstet Gynecol. 2020. PMID: 33096092. doi:10.1016/j.ajog.2020.10.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。